Summary

Global Coagulation Factor Deficiency Market, Analysis and Forecast: 2025-2035

Coagulation factor deficiency is a blood clotting disorder where one or more of the proteins (clotting factors) necessary for normal blood coagulation are either missing or not functioning properly. This results in the blood's inability to form clots effectively, leading to excessive bleeding or difficulty stopping bleeding after injury or surgery. The most common coagulation factor deficiencies include Hemophilia A (deficiency of Factor VIII), Hemophilia B (deficiency of Factor IX), and Von Willebrand Disease (deficiency or dysfunction of Von Willebrand factor). Coagulation factor deficiencies can be inherited, with conditions such as Hemophilia A and B being X-linked recessive, meaning they are more commonly seen in males. However, some factor deficiencies can also be acquired due to conditions that affect the blood’s clotting ability, such as liver disease or certain autoimmune disorders. These deficiencies often require ongoing treatment with clotting factor concentrates or gene therapy to prevent or control bleeding episodes and manage the condition effectively.

One of the key drivers of the coagulation factor deficiency market is the advancement in treatment options, particularly the development of long-acting recombinant clotting factors and gene therapies. These innovations offer significant improvements over traditional treatments, which typically require frequent infusions of clotting factors. Long-acting recombinant clotting factors, for example, reduce the need for regular infusions, making treatment more convenient for patients and improving their quality of life. Additionally, gene therapy, which aims to provide a potential cure by addressing the genetic defects underlying conditions such as Hemophilia A and Hemophilia B, is gaining traction as a groundbreaking solution. As gene therapy continues to show positive results in clinical trials, it promises long-term or even curative benefits, further driving demand for coagulation factor deficiency treatments. These advancements are contributing to increased market growth as they offer patients more effective, personalized, and less burdensome treatment options.

Despite the growth of the coagulation factor deficiency market, several challenges continue to impede its full potential. One major challenge is the high cost of treatment, particularly for advanced therapies such as gene therapy and long-acting recombinant clotting factors. These therapies, while promising, come with significant upfront costs, which can be a barrier to access for many patients, especially in low- and middle-income countries. The high cost not only limits affordability for individual patients but also places a strain on healthcare systems, making it difficult for governments and insurers to provide widespread access to these cutting-edge treatments. As a result, the treatment burden on patients remains substantial, and access to life-saving therapies remains unequal, limiting the market’s growth potential despite the availability of innovative treatments.

The global coagulation factor deficiency market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Hoffmann-La Roche Ltd and Novo Nordisk A/S are at the forefront, developing advanced therapies such as long-acting recombinant clotting factors and gene therapies for Hemophilia A and Hemophilia B. Pfizer Inc., known for its broad portfolio, continues to expand its offerings in this space, while Grifols, S.A. is making strides with its plasma-derived therapies for coagulation disorders. Additionally, companies such as Alnylam Pharmaceuticals and Sangamo Therapeutics are exploring novel approaches, including gene silencing and gene editing techniques, to provide more effective and personalized treatments. These industry leaders are continually working to improve patient outcomes through innovative therapies and strategic collaborations, enhancing their competitive edge in the coagulation factor deficiency market.

Market Segmentation:

Segmentation 1: by Deficiency Type
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Factor XI & Factor XIII Deficiencies
• Other Deficiencies

Segmentation 2: by Product Type
• Recombinant Coagulation Factors
• Plasma-derived Coagulation Factors
• Others

Segmentation 3: by End-User
• Hospitals
• Specialty Clinics
• Others

Segmentation 4: by Region
• North America
• Europe
• Asia-Pacific

The global coagulation factor deficiency market is experiencing several key emerging trends that are reshaping the landscape of diagnosis and treatment. One prominent trend is the increasing use of gene therapy, which holds the potential to provide long-term or curative solutions for conditions such as Hemophilia A and Hemophilia B. This approach is gaining traction as it directly addresses the genetic defects responsible for these coagulation disorders, reducing the need for lifelong treatments with clotting factor concentrates. Additionally, the market is seeing a rise in the development of long-acting recombinant clotting factors, which improve patient convenience by reducing the frequency of infusions. Another emerging trend is the advancement of personalized medicine, where treatments are tailored to individual genetic profiles, offering more effective and precise care for patients. With these innovations, the coagulation factor deficiency market is moving toward more efficient, patient-centric solutions that promise to improve both the quality of life and the long-term management of bleeding disorders.

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. Global Coagulation Factor Deficiency Market: Industry Outlook
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology Analysis
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. Global Coagulation Factor Deficiency Market (Deficiency Type), ($Billion), 2023-2035
2.1 Hemophilia A
2.2 Hemophilia B
2.3 Von Willebrand Disease
2.4 Factor XI Deficiency
2.5 Factor XIII Deficiency
2.6 Others
3. Global Coagulation Factor Deficiency Market (Product Type), ($Billion), 2023-2035
3.1 Plasma-derived Coagulation Factors
3.2 Recombinant Coagulation Factors
3.3 Other
4. Global Coagulation Factor Deficiency Market (End-User), ($Billion), 2023-2035
4.1 Hospitals
4.2 Specialty Clinics
4.3 Others
5. Global Coagulation Factor Deficiency Market (Region), ($Billion), 2023-2035
5.1 North America
5.1.1 Key Findings
5.1.2 Market Dynamics
5.1.3 Market Sizing and Forecast
5.1.3.1 North America Coagulation Factor Deficiency Market, by Country
5.1.3.1.1 U.S.
5.2 Europe
5.2.1 Key Findings
5.2.2 Market Dynamics
5.2.3 Market Sizing and Forecast
5.2.3.1 Europe Coagulation Factor Deficiency Market, by Country
5.2.3.1.1 Germany
5.2.3.1.2 U.K.
5.2.3.1.3 France
5.2.3.1.4 Italy
5.3 Asia Pacific
5.3.1 Key Findings
5.3.2 Market Dynamics
5.3.3 Market Sizing and Forecast
5.3.3.1 Asia Pacific Coagulation Factor Deficiency Market, by Country
5.3.3.1.1 China
5.3.3.1.2 Japan
6. Global Coagulation Factor Deficiency Market: Competitive Landscape and Company Profiles
6.1 Key Strategies and Development
6.1.1 Mergers and Acquisitions
6.1.2 Synergistic Activities
6.1.3 Business Expansions and Funding
6.1.4 Product Launches and Approvals
6.1.5 Other Activities
6.2 Company Profiles
6.2.1 F. Hoffmann-La Roche Ltd
6.2.1.1 Overview
6.2.1.2 Top Products / Product Portfolio
6.2.1.3 Top Competitors
6.2.1.4 Target Customers/End-Users
6.2.1.5 Key Personnel
6.2.1.6 Analyst View
6.2.2 Sanofi S.A.
6.2.2.1 Overview
6.2.2.2 Top Products / Product Portfolio
6.2.2.3 Top Competitors
6.2.2.4 Target Customers/End-Users
6.2.2.5 Key Personnel
6.2.2.6 Analyst View
6.2.3 Grifols, S.A.
6.2.3.1 Overview
6.2.3.2 Top Products / Product Portfolio
6.2.3.3 Top Competitors
6.2.3.4 Target Customers/End-Users
6.2.3.5 Key Personnel
6.2.3.6 Analyst View
6.2.4 Novo Holdings A/S
6.2.4.1 Overview
6.2.4.2 Top Products / Product Portfolio
6.2.4.3 Top Competitors
6.2.4.4 Target Customers/End-Users
6.2.4.5 Key Personnel
6.2.4.6 Analyst View
6.2.5 Pfizer Inc.
6.2.5.1 Overview
6.2.5.2 Top Products / Product Portfolio
6.2.5.3 Top Competitors
6.2.5.4 Target Customers/End-Users
6.2.5.5 Key Personnel
6.2.5.6 Analyst View
6.2.6 Alnylam Pharmaceuticals
6.2.6.1 Overview
6.2.6.2 Top Products / Product Portfolio
6.2.6.3 Top Competitors
6.2.6.4 Target Customers/End-Users
6.2.6.5 Key Personnel
6.2.6.6 Analyst View
6.2.7 Sangamo Therapeutics
6.2.7.1 Overview
6.2.7.2 Top Products / Product Portfolio
6.2.7.3 Top Competitors
6.2.7.4 Target Customers/End-Users
6.2.7.5 Key Personnel
6.2.7.6 Analyst View
6.2.8 Centessa Pharmaceuticals
6.2.8.1 Overview
6.2.8.2 Top Products / Product Portfolio
6.2.8.3 Top Competitors
6.2.8.4 Target Customers/End-Users
6.2.8.5 Key Personnel
6.2.8.6 Analyst View
6.2.9 Staidson Biopharma Inc.
6.2.9.1 Overview
6.2.9.2 Top Products / Product Portfolio
6.2.9.3 Top Competitors
6.2.9.4 Target Customers/End-Users
6.2.9.5 Key Personnel
6.2.9.6 Analyst View
6.2.10 Ultragenyx Pharmaceutical
6.2.10.1 Overview
6.2.10.2 Top Products / Product Portfolio
6.2.10.3 Top Competitors
6.2.10.4 Target Customers/End-Users
6.2.10.5 Key Personnel
6.2.10.6 Analyst View
6.2.11 OPKO Health, Inc.
6.2.11.1 Overview
6.2.11.2 Top Products / Product Portfolio
6.2.11.3 Top Competitors
6.2.11.4 Target Customers/End-Users
6.2.11.5 Key Personnel
6.2.11.6 Analyst View
6.2.12 Novo Nordisk
6.2.12.1 Overview
6.2.12.2 Top Products / Product Portfolio
6.2.12.3 Top Competitors
6.2.12.4 Target Customers/End-Users
6.2.12.5 Key Personnel
6.2.12.6 Analyst View
6.2.13 Takeda Pharmaceutical Company Limited
6.2.13.1 Overview
6.2.13.2 Top Products / Product Portfolio
6.2.13.3 Top Competitors
6.2.13.4 Target Customers/End-Users
6.2.13.5 Key Personnel
6.2.13.6 Analyst View
6.2.14 Biogen Inc
6.2.14.1 Overview
6.2.14.2 Top Products / Product Portfolio
6.2.14.3 Top Competitors
6.2.14.4 Target Customers/End-Users
6.2.14.5 Key Personnel
6.2.14.6 Analyst View
6.2.15 Octapharma AG
6.2.15.1 Overview
6.2.15.2 Top Products / Product Portfolio
6.2.15.3 Top Competitors
6.2.15.4 Target Customers/End-Users
6.2.15.5 Key Personnel
6.2.15.6 Analyst View
7. Research Methodology
List of Figures
Figure: Global Coagulation Factor Deficiency Market (by Region), $Billion, 2024 and 2035
Figure: Global Coagulation Factor Deficiency Market Key Trends, Analysis
List of Tables
Table: Global Coagulation Factor Deficiency Market Dynamics, Impact Analysis
Table: Global Coagulation Factor Deficiency Market (by Region), $Billion, 2024-2035
Table: Global Coagulation Factor Deficiency Market (by Deficiency Type), $Billion, 2024-2035
Table: Global Coagulation Factor Deficiency Market (by Product Type), $Billion, 2024-2035
Table: Global Coagulation Factor Deficiency Market (by End-User), $Billion, 2024-2035

Press Release